Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02038803 · ClinicalTrials.gov registry record
Efficacy of TOBI Podhaler vs. Tobramycin Inhalation Solution
A clinical trial, sponsored by Rush University Medical Center.
- Terminated
- Registry status
- 5
- Enrollment target
NCT02038803 is a clinical trial that was terminated before completion, run by Rush University Medical Center. The registered enrollment target is 5 participants.
The verdict
NCT02038803 was terminated before completion, sponsored by Rush University Medical Center.
- TERMINATED
- Registry status
- 5 participants
- Enrollment target
Study Summary
Inhaled tobramycin is a Cystic Fibrosis Foundation recommended effective treatment for individuals with cystic fibrosis for the management of Pseudomonas aeruginosa airway colonization and improves the FEV1 and reduces the number of acute pulmonary exacerbations of CF. Patients typically use the inhaled tobramycin for a period of 28 days. Unfortunately, the standard nebulizer method for delivering tobramycin inhaled solution (TIS) is time-consuming and may result in missed therapy doses and suboptimal care. A new inhaled formulation and delivery device, the TOBI Podhaler (TPI), an alternative method of administering inhaled Tobramycin will be used and assessed. This new pocket-sized disposable inhaler is maintenance-free, requires no refrigeration or power source, and should greatly increase patient mobility and improve time management.
Interventions
- DRUG TOBIpodhaler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2013-10-10 |
| Est. Completion | 2014-05-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02038803
The ClinicalTrials.gov registry entry for NCT02038803 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TOBIpodhaler is the first listed.
NCT02038803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02038803 about?
NCT02038803 is a clinical study titled "Efficacy of TOBI Podhaler vs. Tobramycin Inhalation Solution". Inhaled tobramycin is a Cystic Fibrosis Foundation recommended effective treatment for individuals with cystic fibrosis for the management of Pseudomonas aeruginosa airway colonization and improves the FEV1 and reduces the number of acute pulmonary exacerbations of CF. Patients typically use the inh...
What is the current status of trial NCT02038803?
This trial is currently terminated. The enrollment target is 5 participants. The study started on 2013-10-10. Estimated completion is 2014-05-07.
What interventions are being tested in trial NCT02038803?
The interventions under investigation include: TOBIpodhaler (DRUG).
Who is sponsoring clinical trial NCT02038803?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.